10 results
DEFA14A
AGIO
Agios Pharmaceuticals Inc
15 Mar 21
Additional proxy soliciting materials
5:14pm
that the Proxy Statement omitted material information with respect to the Transaction. The plaintiff seeks that the Company provide supplemental … on Form 8-K. The plaintiff has agreed that, following the filing of this Current Report on Form 8-K, he will consider his claims mooted and will refrain
8-K
AGIO
Agios Pharmaceuticals Inc
15 Mar 21
Other Events
5:11pm
omitted material information with respect to the Transaction. The plaintiff seeks that the Company provide supplemental disclosures in an amendment … liability or wrongdoing, the Company is voluntarily supplementing the Proxy Statement as described in this Current Report on Form 8-K. The plaintiff
DEFM14A
AGIO
Agios Pharmaceuticals Inc
11 Feb 21
Proxy related to merger
4:19pm
of the transaction. Accordingly, if litigation is filed challenging the transaction and a plaintiff is successful in obtaining an order enjoining
PREM14A
AGIO
Agios Pharmaceuticals Inc
29 Jan 21
Preliminary proxy related to merger
4:22pm
the transaction and a plaintiff is successful in obtaining an order enjoining completion of the transaction, then such order may prevent the transaction
8-K
EX-1.1
p4v16s
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
8-K
EX-1.1
4zy7jk
11 Dec 14
Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock
12:00am
S-1
EX-4.2
le6dyl fb6dzokf0temt
10 Jun 13
IPO registration
12:00am
- Prev
- 1
- Next